China Securities News reporter learned from the online media conference held by Herui gene on May 18 that Herui gene has officially launched the hifi technology system with high barriers recently, and plans to market the early screening products for one-time detection of six tumor species based on the hifi technology system in 2022. It is expected to expand the tumor species horizontally, improve the performance vertically and continuously optimize the hifi technology system in the next few years, Finally, the development and delivery of “20 +” tumor early screening products for one-time detection will be realized.
It is reported that hifi technology system is composed of hifi det liquid biopsy technology and corresponding hifi cal series algorithms. The advantage of hifi technology system is that it can maintain the iteration and ductility of the core model through the iterative optimization of markers and early warning prediction model, continuously optimize its performance, reduce the technical cost, avoid the problem of increasing cost caused by increasing omics and dimensions, and make the cost of early screening technology controllable.
With the commercial application of NGS technology, it can sequence billions of DNA molecules at the same time, overcome the deficiency that previous monoomics research can only obtain information in a single dimension, and improve the overall performance of cancer detection products.
It is reported that since its establishment, Herui gene has carried out the selection of cancer biomarkers through multi omics based on ngs platform. At the same time, combined with the corresponding deep learning model, Herui gene has developed products covering the whole course of cancer, including early screening and early diagnosis, small lesion residue and recurrence monitoring.
It is reported that in August 2020, Herui gene’s first clinical liver cancer early screening product “laisining” was listed. Based on this, through whole genome sequencing and corresponding analysis algorithms, Herui gene has built an early warning and prediction model for multi-dimensional and low-frequency variation information of multi omics, including tumor early driving gene mutation, structural variation and epigenetics, and gradually formed the hifi technology system. Based on this technology, Herui gene has published the performance data of early screening for some liver cancer and multiple tumor species (liver cancer, lung cancer, gastric cancer, colorectal cancer, esophageal cancer and pancreatic cancer): the sensitivity of early screening for liver cancer is 95.42% and the specificity is 97.91%; The sensitivity of multi tumor early screening was 87.58% and the specificity was 99.09%.
Wu Jiayan, President of Herui Gene Research Institute, said that cancer research based on ngs platform has become a global technology trend. “The hifi technology system accumulated in the past few years has shown superior performance. We believe that early screening of cancer and even the product form of the whole course of cancer will follow this idea in the future.”
Zhang Yue, director of Strategic Development Department of Herui gene, said that the difference between multi tumor products and single tumor products is that they are oriented to different groups. Generally, single tumor products are oriented to high-risk groups of a certain cancer, and multi tumor early screening is oriented to larger groups. Therefore, it puts forward new tests for the company in terms of performance and commercialization.
“Paying and proving the economic value of health is still a difficult problem for the whole industry.” Zhang Yue said that in foreign countries, head companies such as grail began to cooperate with institutions such as NHS to prove the value of early screening of cancer in the medical system. The accumulation of these evidences plays a key role in promoting Payment institutions such as medical insurance and commercial insurance to include cancer early screening products or services based on liquid biopsy.
Zhou Jun, CEO of Herui gene, said: “as a national enterprise, in the future, Herui gene will not only carry out the development and transformation of more cutting-edge technologies, but also take into account the optimal solution of cost and performance, and cooperate with all parties including insurance and internet medical platform to create a truly innovative and accessible cancer prevention ecosystem.”
